Yen Y Tan

List of Publications by Year
in descending order

48 papers	4,285 citations	331259 21 h-index	205818 48 g-index
52 all docs	52 docs citations	52 times ranked	7399 citing authors

#	Article	IF	Citations
1	Breast and Prostate Cancer Risks for MaleBRCA1andBRCA2Pathogenic Variant Carriers Using Polygenic Risk Scores. Journal of the National Cancer Institute, 2022, 114, 109-122.	3.0	19
2	Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. Journal of Clinical Oncology, 2022, 40, 1529-1541.	0.8	90
3	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	1.4	23
4	Abstract P4-12-10: Cancer worry among healthy BRCA mutation carriers in Austria: A pilot study. Cancer Research, 2022, 82, P4-12-10-P4-12-10.	0.4	0
5	Patient satisfaction after breast cancer surgery. Wiener Klinische Wochenschrift, 2021, 133, 6-13.	1.0	11
6	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	1.1	16
7	Reliability of Tumor Testing Compared to Germline Testing for Detecting BRCA1 and BRCA2 Mutations in Patients with Epithelial Ovarian Cancer. Journal of Personalized Medicine, 2021, 11, 593.	1.1	11
8	Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. American Journal of Obstetrics and Gynecology, 2021, 225, 51.e1-51.e17.	0.7	34
9	Cancer Spectrum, Family History of Cancer and Overall Survival in Men with Germline BRCA1 or BRCA2 Mutations. Journal of Personalized Medicine, 2021, 11, 917.	1.1	3
10	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.4	39
11	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	9.4	120
12	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. Genetics in Medicine, 2020, 22, 1653-1666.	1.1	82
13	Receptor Discordance of Metastatic Breast Cancer Depending on the Molecular Subtype. Breast Care, 2020, 15, 648-654.	0.8	3
14	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	3.4	48
15	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 368-378.	1.1	24
16	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2020, 22, 8.	2.2	41
17	Association of Cytokeratin 5 and Claudin 3 expression with BRCA1 and BRCA2 germline mutations in women with early breast cancer. BMC Cancer, 2019, 19, 695.	1.1	4
18	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2019, 121, 180-192.	2.9	19

#	Article	IF	Citations
19	Association between family history, mutation locations, and prevalence of BRCA1 or 2 mutations in ovarian cancer patients. Cancer Medicine, 2019, 8, 1875-1881.	1.3	17
20	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. Journal of the National Cancer Institute, 2019, 111, 350-364.	3.0	30
21	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	1.1	224
22	The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With BRCA1 or BRCA2 Mutations. JNCI Cancer Spectrum, 2018, 2, pky078.	1.4	21
23	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. JNCI Cancer Spectrum, 2018, 2, pky023.	1.4	33
24	Endometrial cancer risk and survival by tumor MMR status. Journal of Gynecologic Oncology, 2018, 29, e39.	1.0	34
25	Improving comprehension of genetic counseling for hereditary breast and ovarian cancer clients with a visual tool. PLoS ONE, 2018, 13, e0200559.	1.1	11
26	Differential Claudin 3 and EGFR Expression Predicts BRCA1 Mutation in Triple-Negative Breast Cancer. Cancer Investigation, 2018, 36, 378-388.	0.6	8
27	Pathological Complete Response to Neoadjuvant Trastuzumab Is Dependent on HER2/CEP17 Ratio in HER2-Amplified Early Breast Cancer. Clinical Cancer Research, 2017, 23, 3676-3683.	3.2	29
28	Expression of ezrin and moesin in primary breast carcinoma and matched lymph node metastases. Clinical and Experimental Metastasis, 2017, 34, 333-344.	1.7	17
29	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA - Journal of the American Medical Association, 2017, 317, 2402.	3.8	1,898
30	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	9.4	356
31	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	9.4	289
32	Family history of cancer predicts endometrial cancer risk independently of Lynch Syndrome: Implications for genetic counselling. Gynecologic Oncology, 2017, 147, 381-387.	0.6	30
33	Identification and management of familial breast cancer in Austria. Hormone Molecular Biology and Clinical Investigation, 2017, 32, .	0.3	2
34	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. Breast Cancer Research and Treatment, 2017, 161, 117-134.	1.1	18
35	Diagnostic markers for the detection of ovarian cancer in BRCA1 mutation carriers. PLoS ONE, 2017, 12, e0189641.	1.1	8
36	Estradiol impairs the antiproliferative and proapoptotic effect of Zoledronic acid in hormone sensitive breast cancer cells in vitro. PLoS ONE, 2017, 12, e0185566.	1.1	7

#	Article	IF	Citations
37	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. Journal of Clinical Oncology, 2017, 35, 2240-2250.	0.8	152
38	PTEN expression as a predictor for the response to trastuzumab-based therapy in Her-2 overexpressing metastatic breast cancer. PLoS ONE, 2017, 12, e0172911.	1.1	12
39	Association of family history and location of BRCA1 and BRCA2 mutations in triple-negative breast cancer patients.. Journal of Clinical Oncology, 2017, 35, e12588-e12588.	0.8	0
40	Cadherin-11 expression is upregulated in invasive human breast cancer. Oncology Letters, 2016, 12, 4393-4398.	0.8	21
41	RANKL/RANK control Brca1 mutation-driven mammary tumors. Cell Research, 2016, 26, 761-774.	5.7	128
42	Barriers and Motivators for Referral of Patients with Suspected Lynch Syndrome to Cancer Genetic Services: A Qualitative Study. Journal of Personalized Medicine, 2014, 4, 20-34.	1.1	18
43	Knowledge, Attitudes and Referral Patterns of Lynch Syndrome: A Survey of Clinicians in Australia. Journal of Personalized Medicine, 2014, 4, 218-244.	1.1	9
44	Reply to J. Moline et al. Journal of Clinical Oncology, 2014, 32, 2278-2279.	0.8	5
45	Tumor Mismatch Repair Immunohistochemistry and DNA MLH1 Methylation Testing of Patients With Endometrial Cancer Diagnosed at Age Younger Than 60 Years Optimizes Triage for Population-Level Germline Mismatch Repair Gene Mutation Testing. Journal of Clinical Oncology, 2014, 32, 90-100.	0.8	195
46	Improving identification of lynch syndrome patients: A comparison of research data with clinical records. International Journal of Cancer, 2013, 132, 2876-2883.	2.3	26
47	Referral of Patients with Suspected Hereditary Breast-Ovarian Cancer or Lynch Syndrome for Genetic Services: A Systematic Review. , 2013, 03, .		4
48	Gender differences in risk factors for coronary heart disease. Maturitas, 2010, 65, 149-160.	1.0	88